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http://www.biomedcentral.com/1471-2121/15/30RESEARCH ARTICLE Open AccessMXD3 regulation of DAOY cell proliferation
dictated by time course of activation
Tin Ngo1,2, Gustavo A Barisone1, Kit S Lam2 and Elva Dίaz1*Abstract
Background: MXD3 is a basic-helix-loop-helix-leucine-zipper transcription factor involved in cellular proliferation.
In previous studies we demonstrated that knock-down of MXD3 in the human medulloblastoma cell line DAOY
resulted in decreased proliferation. Surprisingly, overexpression of MXD3 in DAOY cells also decreased proliferation
and increased cell death, suggesting that persistent expression of MXD3 triggers an apoptotic response, perhaps as
a fail-safe mechanism. To investigate this apparent paradox in detail we developed a tamoxifen inducible system
to analyze the temporal effects of MXD3 in the proliferation and transcriptional response of DAOY cells upon acute
induction compared with long-term expression of MXD3.
Results: We find that acute induction of MXD3 initially promotes cell cycle progression as assessed by a transient
increase in bromodeoxyuridine incorporation. However, persistent induction of MXD3 ultimately results in decreased
proliferation based on cell counts. Finally, with microarray expression profiling and gene ontology analysis we identify
several major pathways enriched in response to acute (immune response, apoptosis, cell cycle) versus persistent (cell
adhesion) MXD3 activation.
Conclusions: In this study, we demonstrate that acute MXD3 activation results in a transient increase in cell proliferation
while persistent activation of MXD3 eventually results in an overall decrease in cell number, suggesting that the time
course of MXD3 expression dictates the cellular outcome. Microarray expression profiling and gene ontology analysis
indicate that MXD3 regulates distinct genes and pathways upon acute induction compared with persistent
expression, suggesting that the cellular outcome is specified by changes in MXD3 transcriptional program in a
time-dependent manner.
Keywords: MXD3, Proliferation, Medulloblastoma, DAOYBackground
Medulloblastoma, the most common brain tumor in
children [1], develops due to uncontrolled proliferation
of cerebellar granule neuron precursors (GNPs) [2]. A
large body of literature exists regarding the molecular
mechanisms of medulloblastoma formation and progres-
sion. Thus far, four subtypes of medulloblastomas have
been identified including the Wnt and Sonic hedgehog
(Shh) subgroups [3,4]. Medulloblastomas of the Shh sub-
group have mutations in upstream components of the
Shh pathway, including the receptors PTCH and SMO
[4]. PTCH, when bound by Shh, relieves its inhibition
of SMO [5] which then initiates a complex cascade of* Correspondence: ediaz@ucdavis.edu
1Department of Pharmacology, UC Davis School of Medicine, 451 Health
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unless otherwise stated.events leading to cell cycle progression. One example of
an established mechanism for Shh pathway-dependent
cell cycle progression is through the upregulation of
cyclins by the proto-oncogene MYCN [6]. Mutation of
downstream targets of Shh such as GLI1, GLI2 [7], and
MYCN is a characteristic of medulloblastomas within
the Shh subtype [4]. However, the molecular mechanisms
behind medulloblastoma formation and progression are
not completely understood. Indeed, recent evidence sug-
gests that a subset of cerebellar granule neurons originate
not from GNPs but from a population of Nestin-expressing
progenitors (NEPs) in the deep external germinal layer and
that these NEPs are more susceptible to Shh-dependent
tumor formation [8].
Previously, our lab identified the transcription factor
MXD3 as a critical regulator of GNP proliferation dur-
ing normal cerebellar development as a downstream. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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found that MXD3 is overexpressed in tumor tissue from
the PTCH deficient heterozygote mouse model of me-
dulloblastoma [9]. Moreover, recently we showed that
MXD3 is upregulated in human medulloblastomas and
is required for the proliferation of the human medullo-
blastoma cell line DAOY [10]. These results suggest a
role for MXD3 in medulloblastoma in humans. The
DAOY cell line was established from a medulloblastoma
tumor mass obtained from a 4 year old patient [11].
Tissue from this tumor had evidence of both neural and
glial differentiation; however, these characteristics were
lost during the establishment of DAOY as a cancer cell
line [11].
MXD3 is a basic-helix-loop-helix-leucine-zipper (bHLHZ)
transcription factor that is part of the MYC/MAX/MXD
transcriptional network [12]. Within this network, MYC
and MXD family members compete with each other for
MAX heterodimerization to invoke opposing transcrip-
tional regulation of target genes [13,14]. Specifically, MYC
and MAX heterodimers recruit transcriptional activators
[15] while MXD and MAX heterodimers recruit transcrip-
tional repressors [13,16,17]. MYC family members have
been shown to promote while MXD family members have
been shown to repress cell cycle progression [18]. MXD3,
however, is an atypical member of the MXD family as it
has been found to be expressed during the S-phase of the
cell cycle [9,19,20] while other MXD family members
are expressed in differentiated cells [14]. Knockdown of
MXD3 leads to a reduction in cell number suggesting that
MXD3 is required for cell cycle progression [9,10]. On the
other hand, overexpression of MXD3 is sufficient to pro-
mote proliferation in mouse cerebellar GNPs [9]. Consist-
ent with these results, overexpression of MXD3 negatively
regulates differentiation in mouse B cells derived from the
spleen [21]. Persistent overexpression of MXD3, however,
in mouse GNPs and in human medulloblastoma cells re-
sults in decreased proliferation due to the activation of
apoptosis [9,10].
To characterize MXD3 overexpression in a time
dependent manner, we engineered the DAOY cell line
to express stably a fusion protein between the trun-
cated Estrogen Receptor and MXD3 (ER-MXD3). In
contrast to endogenous MXD3, which is localized to
the nucleus [22], under baseline conditions the ER-
MXD3 fusion protein is enriched in the cytoplasm.
Upon treatment of 4-hydroxytamoxifen (4-OHT) the
ER-MXD3 fusion protein translocates into the nucleus
allowing for the timed activation of MXD3. Here we
show that the nuclear translocation of ER-MXD3 ini-
tially leads to a transient increase in cell proliferation
based on bromodeoxyuridine (BrdU) incorporation but
ultimately results in an overall decrease in cell number.
Furthermore, we identify candidate MXD3 regulatedgenes upon acute induction and long-term expression
to investigate the opposing activities of MXD3 in the
regulation of cellular proliferation in DAOY cells.
Results and discussion
ER-MXD3 translocates into the nucleus upon
4-OHT treatment
We have previously shown that MXD3 knock-down re-
duced proliferation of DAOY medulloblastoma cells,
while persistent overexpression also decreased cellular
proliferation [10]. To distinguish between MXD3’s
acute versus long-term effects in DAOY medulloblas-
toma cells, we developed 4-OHT inducible cell lines
that express MXD3 as a fusion to a portion of the
mouse estrogen receptor (254 C-terminal amino acid
residues, lacking its DNA-binding domain). Further-
more, we have previously found that MXD3 activity is
abolished upon mutation of a single amino acid at the
66th position in the basic domain of MXD3 (MXD3.
E66D) [10]. The E66D mutation has been shown to
disrupt the basic domain binding of other bHLH pro-
teins to the E-box DNA sequence in gel shift assays
[23]. Therefore, as a negative control for subsequent
experiments, we developed cell lines stably expressing
the inducible fusion ER-MXD3.E66D for comparison.
The fusion protein, ER-MXD3, is expected to be
expressed predominantly in the cytoplasm (where it
has no known or expected function as a transcription
factor) and only translocate to the nucleus (and thus
exert its function by binding to target DNA sequences)
upon 4-OHT treatment. We confirmed that our cell
lines express the respective fusion proteins, ER-MXD3
or ER-MXD3.E66D (Figure 1A and Additional file 1:
Figure S1) with no observable degradation or cleavage
products (Additional file 2: Figure S2) by immunoblot.
Furthermore, the fusion proteins translocate into the
nucleus within 1 hour of 4-OHT treatment by im-
munocytochemistry (Figure 1B). Under vehicle treat-
ment, the fusion protein is present in the cytoplasm as
expected but some protein is present in the nucleus
(Figure 1B, top panels). This result can be explained by
an inherent leakiness within the system or by the pres-
ence of trace amounts of an analog of estrogen within
the culture media or the cells themselves. We also ob-
serve similar results in immunoblotting experiments
after biochemical fractionation of nuclear and cyto-
plasmic components of lysates from our inducible cell
lines (Additional file 3: Figure S3). Despite this leaki-
ness, based on the enriched nuclear staining pattern of
the fusion protein under 4-OHT conditions (Figure 1B,
bottom panels) and the relative localization to the nu-
clear fraction (Additional file 3: Figure S3), the system
can be used for the timed induction of MXD3 tran-
scriptional activity upon nuclear translocation. This
Figure 1 Characterization of the 4-OHT inducible cell lines. (A) Extracts from stable cell lines immunoblotted for HA and Tubulin (loading
control). DAOY extracts (lane 1) show no expression of HA, while extracts from ER-MXD3.E66D (lane 2) and ER-MXD3 (lane 3) show an expected
band of approximately 68 kDa. (B) Confocal images of the ER-MXD3 cell line treated with either ethanol (top panels) or 1 μM 4-OHT (bottom panels) for 1
hour and stained for DAPI, HA, and MXD3. When treated with 4-OHT the ER-MXD3 fusion protein is primarily localized in the nucleus (identified by DAPI
staining) in contrast to vehicle (ethanol) treatment in which the fusion protein is localized throughout the cell. Scale bar 20 μm.
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mediate and long-term effects of MXD3 activation.
MXD3 activation results in a transient increase in BrdU
incorporation followed by a decrease in cell counts
MXD3 has been shown to increase GNP proliferation as
measured by BrdU incorporation [9]. To characterize
MXD3 in DAOY cells in a time dependent manner, we
used our stable cell lines in proliferation assays in which
we measured BrdU incorporation in response to MXD3
activation (Figure 2). Two-way ANOVA analysis reveals
that there is a significant difference between ethanol vs.
4-OHT treatment in the ER-MXD3 cell line (p = 0.0487)
but not in the control ER-MXD3.E66D cell line (p =
0.1595). Bonferroni post-tests show that after 8 hours of
4-OHT treatment there was a significant increase (p < 0.01)
in BrdU incorporation in the ER-MXD3 line (Figure 2).
This effect peaked at 12 hours post treatment with a signifi-
cant increase (p < 0.001) of 1.33-fold over vehicle in ER-MXD3. Subsequently, BrdU incorporation returns to
baseline (vehicle treated) levels by 72 hours.
As shown in Figure 3 and Additional file 4: Figure S4,
however, long-term MXD3 activation results in reduced cell
counts, consistent with our previous studies [9,10]. The re-
duction in cell counts is statistically significant (p < 0.0001)
by two-way ANOVA analysis. Bonferroni post-tests reveal
that there is a significant difference (p < 0.001) by 4 days
post treatment between 4-OHT treated vs. vehicle control
(Figure 3A). No significant difference was observed be-
tween 4-OHT and vehicle treated in control ER-MXD3.
E66D (p = 0.4468) (Figure 3B) and parental DAOY (p =
0.8562) (Figure 3C) cell lines, indicating that this effect is
specific to the ER-MXD3 line. Furthermore, these results
demonstrate that E-box dependent MXD3 DNA binding is
essential for the observed phenotype. ER-MXD3 cells
treated with 4-OHT at three times the original seeding
density also led to a significant decrease (p < 0.001) in cell
number by 48 hours post-treatment (Additional file 5:
Figure 2 MXD3 activation induces a transient increase in BrdU
incorporation. Bromodeoxyuridine proliferation assay of ER-MXD3.
E66D and ER-MXD3 cell lines treated with 1 μM 4-OHT normalized
to vehicle. Treatments were staggered such that all conditions were
assayed at the same time for BrdU incorporation after a 2 hour BrdU
pulse. ER-MXD3 significantly (p = 0.0487, two-way ANOVA, n = 8)
responds to 4-OHT treatment compared to vehicle, whereas
ER-MXD3.E66D does not. Results of bonferroni post-test analysis
comparing 4-OHT to vehicle are noted with asterisks.
Figure 3 Persistent MXD3 activation leads to decreased cell
counts. Cell counts of (A) ER-MXD3, (B) ER-MXD3.E66D, and (C)
DAOY cell lines over 7 days represented as fold change relative to
initial seeding density. ER-MXD3 cell line significantly (p < 0.0001,
two-way ANOVA, n = 6) responds to 4-OHT treatment compared to
vehicle treatments. Whereas control ER-MXD3.E66D and DAOY lines
are unaffected by 4-OHT treatment compared to vehicle treatments.
Bonferroni post-test analysis results are noted with asterisks.
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vation does not depend on seeding density. On the other
hand, withdrawal of 4-OHT after 48 hours failed to signifi-
cantly rescue cell number (Additional file 5: Figure S5).
These results imply that the activation of MXD3 leads to
an irreversible decrease in cell number, likely due to the in-
duction of a program of gene expression upon long-term
expression of MXD3 (see below).
The MXD3 promoter region has been shown to be
regulated by the transcription factor E2F1 [24], a critical
transcriptional activator for the transition from the G1
to the S phase of the cell cycle (reviewed in [25]). In
agreement, several groups have shown that MXD3 is
expressed specifically in the S phase of the cell cycle
[9,19,20]. The timing of MXD3 expression suggests that
it may play a role in cell cycle progression through the S
phase. In support of this possibility, it has been observed
that a transient increase in proliferation occurs in both
normal mouse GNPs [9] and now in this study of human
medulloblastoma cells (Figure 2). The fact that this ob-
servation was made in both models suggests that the
phenotype observed in response to MXD3 overexpres-
sion is a conserved aspect of MXD3 function.
Additionally, the overall decrease in cellular prolifera-
tion in response to persistent MXD3 overexpression is
also true in both normal [9] and diseased [10] (Figure 3)
models. This decrease in proliferation can be explained
by the activation of apoptosis as a fail-safe mechanism
upon persistent overexpression beyond the S phase of
the cell cycle. Such a mechanism exists for oncogenessuch as the transcriptional network relative MYC [26,27].
In support of this possibility, both transient overexpression
of MXD3 in GNPs [9] and stable MXD3 overexpression in
human medulloblastoma cell lines [10] show an increase in
apoptosis. When we examined apoptosis activity at 72
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any significant difference in caspase 3/7 activity in response
to MXD3 activation (Additional file 6: Figure S6); however,
there is a trend towards increased caspase 3/7 activity at 72
hours for ER-MXD3, consistent with the decreased cell
number observed. Interestingly, the maximal response to
hydrogen peroxide treatment (used as a positive control in
this assay) in the ER-MXD3 line was 0.608-fold less when
compared to the control ER-MXD3.E66D cell line
(Additional file 6: Figure S6), suggesting that the cap-
acity of the ER-MXD3 cell line to undergo apoptosis is
reduced even in the absence of MXD3 induction. The
inherent leakiness in our inducible system could ac-
count for this difference between the cell lines. If this
is true then it would suggest that at low nuclear
concentrations MXD3 functions as an anti-apoptotic
factor leading to the subsequent difference in the
response to hydrogen peroxide under baseline condi-
tions. Further experimentation will be necessary to test
this intriguing possibility.
Distinct patterns of gene expression are observed upon
acute versus long-term MXD3 activation
The results presented thus far indicate that MXD3 has a
dual role in DAOYcell proliferation, as we suggested before
[10], and that its role is dependent on how long MXD3 is
active or present in the nucleus. We report here an initial
burst in proliferation (as measured by BrdU incorporation
within 12–24 hours) followed by decreased cell counts (at
72 hour) upon MXD3 translocation to the nucleus. Some
remaining questions, then, are whether the observed
phenotypes due to MXD3 activation are the result of two
distinct mechanisms and/or whether the observed pheno-
types are the direct result of MXD3 function. These ques-
tions remain for both normal and diseased models. To
begin to address these questions in the context of human
medulloblastoma, we examined the pathways changed in
response to MXD3 activation in our inducible cell lines.
To this end, we conducted microarray experiments
to compare gene expression between the “early” (in-
creased BrdU incorporation) and “late” (decreased cell
counts) effects of MXD3 overexpression. Samples were
taken from 12 and 72 hours post treatment from both
ER-MXD3 and ER-MXD3.E66D cell lines, in order to
define acute and long-term changes in the pattern of
gene expression elicited by MXD3. Differentially expressed
genes were defined as those genes that showed greater than
2-fold changes in ER-MXD3 (4-OHT/vehicle) over ER-
MXD3.E66D (4-OHT/vehicle). It should be noted that this
approach aimed at identifying changes that require MXD3
binding to the DNA through its basic domain, as this
interaction has been reported to be disrupted in the E66D
mutation [10,23,28-30]. A complete list of differentially
expressed genes is presented in Additional file 7: Table S1.Gene ontology analysis of these results is presented in
Figure 4. Using MetaCore analysis software, a comparison
experiment was performed between differentially expressed
genes at 12 hours (“early”) versus 72 hours (“late”). Gene
intersection (Figure 4A) showed 2,578 unique early genes
(orange bars) and 3,325 unique late genes (blue bars); 2,341
genes were differentially expressed in both time points
(striped bars). Pathway comparison analysis is shown in
Figures 4B-D. The 50 most differentially affected pathways
were grouped according to whether they are mostly repre-
sented in the 12-hour data set (Figure 4B) or the 72-hour
data set (Figure 4C), or similarly represented in both
(Figure 4D). Overall, the 12 hour data set is characterized
by pathways related to immune response, apoptosis, and
cell cycle regulation. This result is consistent with the
proliferative phenotypes we report in this paper; the actual
outcome at a specific time is likely the result of the balance
between apoptotic and proliferative signals. The immune
response pathway might indicate that medulloblastoma
cells are undergoing a stress response upon MXD3 activa-
tion. The most differentially affected pathways at 72 hours
(Figure 4C) include cell adhesion related genes. It can be
hypothesized, then, that long term expression of MXD3
results in transcriptional modulation of genes that might
explain the observed decrease in cell number due to loss of
cell adhesion. The most significantly affected pathways at
both time points (Figure 4D) include VEGF signaling, the
TGF/WNT pathways, cell cycle regulation, and cytoskeletal
remodeling. Interestingly, the Hedgehog (Hh) pathway is
also affected. While these pathways are all relevant to sev-
eral aspects of cancer biology (cell proliferation, migration,
metastasis, anchorage independent growth), it is especially
important to note the effect of MXD3 overexpression on
the Hh pathway, consistent with previous results from our
laboratory [9]. Affected genes in or related to the Hh path-
way are presented in Figure 5. Interestingly, SHH was
found to be upregulated (predominantly at 72 hours), while
SMO was upregulated after 12 hours of MXD3 overexpres-
sion in the nucleus. Upregulation of SMO could therefore
represent an early response leading to Hh mediated prolif-
eration, while subsequent overexpression of SHH could
represent an autocrine and/or paracrine proliferative signal.
Differentially regulated genes in the cell cycle, VEGF and
WNT pathways are presented in Additional file 8: Figures
S7, Additional file 9: Figure S8 and Additional file 10:
Figure S9. For the complete pathway enrichment analysis,
see Additional file 11: Figure S10 and Additional file 12:
Table S2. Select target genes from each pathway identified
were validated by qRT-PCR (Additional file 13: Table S3).
Conclusions
In this study, we use 4-OHT inducible human medulloblas-
toma cell lines to show that MXD3 activation results in a
transient increase in cell proliferation. In corroboration
Figure 4 Gene ontology pathway analysis. Gene ontology analysis of differentially expressed genes (>2-fold) in ER-MXD3 cells versus ER-E66D
cells. (A) Overall gene content of the dataset analyzed. Differentially expressed genes at 12 hours (orange bar), 72 hours (blue bar) or both (striped
bar) are shown. Canonical pathway enrichment comparison, showing most hits that are more significant for (B) 12 hours or (C) 72 hours, or (D)
common to both. Bars colors are as in (A), and their heights represent the p value for a particular set.
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Figure 5 MXD3 effect on the Hedgehog pathway. MXD3 activation resulted in differentially expressed gene in the Hh pathway. Thermometer-like
icons represent levels of upregulation or downregulation for each specific gene in the 12 hour (➀) or 72 hour (➁) dataset.
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eventually results in an overall decrease in cell number.
With microarray expression profiling we report candi-
date downstream targets of MXD3 differentially regulated
upon acute versus persistent expression of MXD3. Lastly,
with gene ontology analysis we identify several major path-
ways enriched in response to acute (immune response,
apoptosis, cell cycle) versus persistent (cell adhesion)
MXD3 activation that provide insight into the opposingroles of MXD3 in medulloblastoma proliferation in a
time dependent manner.
Methods
Constructs
pCMV-HAER (gift from Peggy Farnham) was the backbone
vector for the constructs used in this study. HA-MXD3
[10] was subcloned into pCMV-HAER using BamHI re-
striction sites to produce pCMV-HA-ER-HA-MXD3 (HA
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The ER-MXD3.E66D mutant construct was produced using
the Quikchange II Site-Directed Mutagenesis Kit (Agilent)
according to manufacturer’s instructions. All constructs
were verified by sequencing.
Cell culture
DAOY cells were acquired from ATCC and were cultured
in a standard humidified incubator (5% CO2, 37°C).
Culture media for DAOY (DAOY media) consisted of
minimum essential media (Invitrogen) supplemented with
10% Fetal Bovine Serum (Invitrogen), 1 mM Sodium
Pyruvate (Invitrogen), 100 μg/ml Penicillin/Strepto-
mycin (Invitrogen). Stable cell lines were maintained
with DAOY media supplemented with 800 μg/ml of
G418 Sulfate (Cellgro).
Transfections and stable cell lines
Transfections were performed with Fugene HD transfec-
tion reagent (Roche) according to the manufacturer’s in-
struction. A 5:2 ratio of DNA to transfection reagent
was used in the initial transfection for the production of
stable cell lines. Briefly, 48 hours after initial seeding, 7
μg of respective constructs was transfected into DAOY
cells. Stable cell lines were established using G418 selec-
tion (800 μg/ml) 48 hours post-transfection of respective
constructs. After one week, cells were passaged to 96-well
plates at 1 cell/well. Clones were expanded and subse-
quently stable expression was confirmed via immunoblot-
ting and immunocytochemistry.
Antibodies
The following primary antibodies were used in this
study: rat anti-HA (Roche), mouse anti-MXD3 (NeuroMab),
mouse anti-β-tubulin (Millipore). Secondary antibodies were
as follows: goat anti-rat-Cy3 (Jackson ImmunoResearch),
donkey anti-mouse-Cy5 (Jackson ImmunoResearch), anti-
goat-horse radish peroxidase (HRP) (Vector Labs), and
anti-mouse-HRP (MP Biomedical).
Immunoblotting
Cell extracts were prepared with lysis buffer at pH 7.4
consisting of 150 mM NaCl, 50 mM Tris, 1% Triton-
X100, 23.4 μM Leupeptin (Roche), 6.1 μM Aproptinin
(Roche), 14.5 μM Pepstatin A (Roche), and 0.1 mM
PMSF (Millipore). Protein concentration was determined
with a Micro BCA Protein assay kit (Thermo Scientific).
Extracts were separated on 12% acrylamide gels under
denaturing and reducing conditions and transferred to
nitrocellulose membranes. Blots were developed using
standard film methods with HRP conjugated secondary
antibodies in conjunction with Luminata Crescendo
HRP substrate (Millipore).Immunocytochemistry
Cells were grown on poly (L)-lysine coated glass cover-
slips in 6-well plates. Upon collection, cells were washed
once with phosphate buffered saline (PBS) and then
fixed with 4% paraformaldehyde (Millipore) and perme-
abilized with 0.01% Triton-X100 in PBS. Coverslips were
then incubated overnight at 4°C with primary antibodies
in 5% bovine serum albumin in PBS. Secondary antibody
incubations were performed in 5% bovine serum albumin
in PBS at room temperature for two hours. Subsequently,
DAPI staining was performed in PBS at room temperature
for 10 minutes. Lastly, coverslips were mounted onto
Superfrost Plus microscope slides (Fisher Scientific) using
Fluoromount-G (SouthernBiotech) and subsequently im-
aged with a LSM 710 confocal microscope (Carl Zeiss).
Proliferation assays
Cells were seeded at 15,000 cells/well in DAOY media
supplemented with ethanol (vehicle) at 1:1000; we found
that ethanol has an initial positive effect on cellular pro-
liferation (data not shown) and thus we seeded cells in
culture media with vehicle in order to account for this
initial effect. After 48 hours, cells were treated with 1
μM 4-OHT (Sigma Aldrich) dissolved in ethanol and
allowed to proliferate. Cells were counted in triplicate
with a Coulter Counter Z1 (Beckman Coulter) after trypsi-
nization. For Bromodeoxyuridine (BrdU) incorporation
measurements, BrdU Cell Proliferation Kit (Millipore) was
used according to the manufacturer’s instructions with cells
seeded at 2×103 cells/well in a 96-well plate. 4-OHT treat-
ment times were staggered such that all samples were proc-
essed and assayed simultaneously for BrdU incorporation
after a two hour incubation with BrdU.
Microarrays and data analysis
RNA samples were purified with an RNeasy kit (Qiagen)
and quality checked using an Agilent Bioanalyzer. Subse-
quent reverse transcription and labeling reactions were
conducted with Amino Allyl MessageAmp II aRNA Kit
(Ambion). cDNA from each time point was collected
and labeled with either Cy3 or Cy5 (source). Two con-
trol samples were generated by pooling all Cy3 or all
Cy5-labeled samples at each time point. Subsequently,
samples were hybridized to Whole Human Genome
4×44K microarrays (Agilent) with their associated op-
posing dye labeled control (e.g. ER-MXD3.12 hours.of.4-
OHT.Cy3 + Pool.of.all.samples.Cy5). Microarrays were
imaged using an Axon GenePix 4000B microarray scan-
ner (Molecular Devices) and feature extraction was con-
ducted using GenePix Pro 6.0. Fluorescence intensity of
features of each sample was normalized to a dye swap
pool. Subsequently, 4-OHT time points were normalized to
the initial time point or vehicle control producing a ratio of
(4-OHT/ethanol). Ratios, then, between ER-MXD3 and
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MXD3 candidate regulated genes. We defined hits as genes
that were up/down-regulated more than two times in ER-
MXD3 (4-OHT/ethanol) compared to ER-MXD3.E66D
(4-OHT/ethanol). Gene ontology analysis was performed
with MetaCore (Thomson Reuters) using the “compare
experiments” module with default parameters.
Statistics
Statistical significance of the BrdU and cell proliferation as-
says was analyzed via two-way ANOVA with Bonferroni
post-tests using GraphPad Prism (GraphPad Software).
Availability of supporting data
The microarray gene expression dataset supporting the
results of this article is available in the Gene Expression
Omnibus (GEO) repository, [GSE5903; http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE58903].
Additional files
Additional file 1: Figure S1. Entire images of the blots in Figure 1 are
shown.
Additional file 2: Figure S2. Immunoblot of DAOY parental and 4-OHT
stable cell lines. HA-ER-HA-MXD3 is expressed as a single fusion protein
with no observable degradation or cleavage products detected by
immunoblot.
Additional file 3: Figure S3. Nuclear and cytosolic fractionation of cell
lysates from control ER-MXD3.E66D and experimental ER-MXD3 lines at
different time points of tamoxifen treatment. Immunoblotting for HA
shows that the fusion proteins disappear from the cytosolic fraction and
subsequently become enriched in the nuclear fraction upon tamoxifen
treatment. GAPDH was used as a loading control and marker of the
cytosolic fraction; histone H3 was used as a loading control and marker
of the nuclear fraction.
Additional file 4: Figure S4. (A-C) Raw cell counts from Figure 3 are
shown. (D) Raw cell counts of the three cell lines treated with vehicle
control (ethanol) are shown on the same graph.
Additional file 5: Figure S5. (A) Cell counts of ER-MXD3 cell lines
treated with 1 μM 4-OHT over 4 days represented as fold change relative
to initial cell counts 24 hours after seeding. (B) At 48 hours after vehicle
treatment, a subset of Ethanol treated cells were subsequently treated
with 1 μM 4-OHT. There was a significant difference between ethanol
and the newly treated 4-OHT cells after 48 hours. (C) At 48 hours after
tamoxifen treatment, 4-OHT was withdrawn from a subset of cells. There
was no significant change upon 4-OHT withdrawal after 48 hours. (D)
Graph depicts results from (A-C).
Additional file 6: Figure S6. Caspase 3/7 activity of control ER-E66D
and experimental ER-MXD3 cell lines treated with either vehicle, 12 hours
of 1 μM 4-OHT, 72 hours of 1 μM 4-OHT, or 6 hours of 150 μM H2O2.
Treatments were staggered such that all samples were collected at the
same time. Caspase 3/7 activity was measured with a Caspase-Glo 3/7
assay kit (Promega) in a 100 μl reaction volume. Specifically, 50 μl of the
caspase detection reagent was substituted with 2x103 cells in 50 μl of
media and incubated for 1 hour in a 96-well white walled/clear bottom
plate. Subsequently, luminescence was detected using a M5 SpectraMax
plate reader (Molecular Devices).
Additional file 7: Table S1. Gene expression profiling of ER-MXD3 cell
line upon treatment with tamoxifen for 12 or 72 hours. Data represent
the fluorescence intensity value normalized to vehicle control. Two-fold
changes in gene expression between ER-MXD3 versus ER-E66D wereconsidered to be differentially expressed upon MXD3 translocation
to the nucleus.
Additional file 8: Figure S7. Role of SCF complex in cell cycle
regulation. Pathway was generated with MetaCore analysis software.
MXD3 activation resulted in differentially expressed gene in the pathway.
Thermometer-like icons represent levels of upregulation or downregulation for
each specific gene in the 12 hour (➀) or 72 hour (➁) dataset.
Additional file 9: Figure S8. VEGF signaling via VEGFR2, generic
cascades. Pathway was generated with MetaCore analysis software.
MXD3 activation resulted in differentially expressed gene in the pathway.
Thermometer-like icons represent levels of upregulation or downregulation
for each specific gene in the 12 hour (➀) or 72 hour (➁) dataset.
Additional file 10: Figure S9. WNT signaling. Pathway was generated
with MetaCore analysis software. MXD3 activation resulted in differentially
expressed gene in the pathway. Thermometer-like icons represent levels
of upregulation or downregulation for each specific gene in the 12 hour
(➀) or 72 hour (➁) dataset.
Additional file 11: Figure S10. Pathway maps enrichment analysis,
sorted by differentially affected pathways. Analysis was performed with
MetaCore analysis software using default parameters.
Additional file 12: Table S2. Pathway enrichment analysis for
differentially expressed genes upon MXD3 activation for 12 or 72 hours.
For each pathway map, the specific genes found to be differentially
expressed are indicated for the common and unique subsets, together
with p value and false discovery rate (FDR).
Additional file 13: Table S3. Validation of select targets from pathways
identified in gene ontology analysis with SYBR green qRT-PCR. Values
for each target gene tested are reported as signal normalized to the vehicle
control and to the E66D control as follows: (MXD3-4-OHT/MXD3-Vehicle)/
(E66D-4-OHT/E66D-Vehicle).
Abbreviation
BrdU: Bromodeoxyuridine; GNPs: Granule Neuron Precursors; bHLHZ:
Basic-helix-loop-helix-leucine-zipper; ER-MXD3: Truncated Estrogen Receptor
and full-length MXD3; 4-OHT: Hydroxytamoxifen; Shh: Sonic hedgehog;
Hh: Hedgehog.
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